130 related articles for article (PubMed ID: 9367703)
1. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
[TBL] [Abstract][Full Text] [Related]
2. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.
van der Hoop RG; Vecht CJ; van der Burg ME; Elderson A; Boogerd W; Heimans JJ; Vries EP; van Houwelingen JC; Jennekens FG; Gispen WH
N Engl J Med; 1990 Jan; 322(2):89-94. PubMed ID: 2152972
[TBL] [Abstract][Full Text] [Related]
3. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ
J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
5. ACTH/MSH like peptides in the treatment of cisplatin neuropathy.
Gispen WH; Hamers FP; Vecht CJ; Jennekens FG; Neyt JP
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):179-83. PubMed ID: 1326318
[TBL] [Abstract][Full Text] [Related]
6. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
7. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial.
van Gerven JM; Hovestadt A; Moll JW; Rodenburg CJ; Splinter TA; van Oosterom AT; Keizer L; Drogendijk TE; Groenhout CM; Vecht CJ
J Neurol; 1994 Jun; 241(7):432-5. PubMed ID: 7931444
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M
Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
10. Protection of cisplatin-induced neuropathy: recent developments.
Hamers F; Neijt J; Gispen W
Pathol Biol (Paris); 1992 Nov; 39(9):829-30. PubMed ID: 1311436
[No Abstract] [Full Text] [Related]
11. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
12. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.
Anticancer Drugs; 1999 Jun; 10(5):465-70. PubMed ID: 10477166
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.
Hilkens PH; van der Burg ME; Moll JW; Planting AS; van Putten WL; Vecht CJ; van den Bent MJ
Eur J Cancer; 1995; 31A(5):678-81. PubMed ID: 7640038
[TBL] [Abstract][Full Text] [Related]
14. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
15. Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: a phase II study.
Hilkens PH; van der Burg ME; Moll JW; van den Bent MJ; van Putten WL; Vecht CJ
Clin Neurol Neurosurg; 1995 May; 97(2):139-41. PubMed ID: 7656487
[TBL] [Abstract][Full Text] [Related]
16. Rationale for the use of the ACTH4-9 analogue ORG 2766 in the treatment of diabetic neuropathy.
Bravenboer B; Erkelens DW; Gispen WH
Neth J Med; 1992 Dec; 41(5-6):255-8. PubMed ID: 1337372
[No Abstract] [Full Text] [Related]
17. [Erythropoietin and cisplatin-induced neuropathies in cancer patients].
Mangiameli A; Spina S; Iannetti E; Catalano D; Spadaro D; Trovato GM
Clin Ter; 2002; 153(3):177-80. PubMed ID: 12161978
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
19. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
